These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908 [TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322 [TBL] [Abstract][Full Text] [Related]
7. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. Karampetsou MP; Liossis SN; Sfikakis PP QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008 [TBL] [Abstract][Full Text] [Related]
8. Upside and Downside of Tumor Necrosis Factor Blockers for Treatment of Immune/Inflammatory Diseases. Kunnumakkara AB; Thakur KK; Rana V; Bora B; Banik K; Khatoon E; Sailo BL; Shabnam B; Girisa S; Gupta SC; Aggarwal BB Crit Rev Immunol; 2019; 39(6):439-479. PubMed ID: 32421957 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy. Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620 [TBL] [Abstract][Full Text] [Related]
10. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Theibich A; Dreyer L; Magyari M; Locht H Clin Rheumatol; 2014 May; 33(5):719-23. PubMed ID: 24202614 [TBL] [Abstract][Full Text] [Related]
11. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
12. Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review. Zhu TH; Nakamura M; Abrouk M; Farahnik B; Koo J; Bhutani T J Dermatolog Treat; 2016 Oct; 27(5):406-13. PubMed ID: 26837667 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease and demyelination: more than just a coincidence? Katsanos AH; Katsanos KH Expert Rev Clin Immunol; 2014 Mar; 10(3):363-73. PubMed ID: 24490959 [TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Bonafede M; Fox KM; Watson C; Princic N; Gandra SR Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712 [TBL] [Abstract][Full Text] [Related]
15. Pathological findings in central nervous system demyelination associated with infliximab. Kalinowska-Lyszczarz A; Fereidan-Esfahani M; Guo Y; Lucchinetti CF; Tobin WO Mult Scler; 2020 Aug; 26(9):1124-1129. PubMed ID: 31845616 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658 [TBL] [Abstract][Full Text] [Related]
17. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769 [TBL] [Abstract][Full Text] [Related]
18. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
19. PAPA Syndrome: Challenges in Achieving Long-Term Remission. Smajlović H; Prohić A Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373 [TBL] [Abstract][Full Text] [Related]